Related Experiment Videos
[The effect of hypolipidemia treatment on the function of kidney transplanted from cadavers]
Insights
Low-dose Lovastatin effectively lowers cholesterol in kidney transplant patients, with no significant increase in adverse events or impact on kidney function over 32 weeks.
Area of Science:
- Nephrology
- Cardiology
- Pharmacology
Background:
- Hypercholesterolemia (HCh) is prevalent in kidney transplant recipients, contributing to cardiovascular mortality and renal failure progression.
- Managing HCh is crucial for improving long-term outcomes in this patient population.
Purpose of the Study:
- To evaluate the safety and efficacy of low-dose Lovastatin in reducing cholesterol levels in kidney transplant recipients.
- To assess the impact of Lovastatin on kidney function and adverse events in this cohort.
Main Methods:
- Prospective, randomized study involving 42 kidney transplant recipients with stable renal function.
- Patients received either 20 mg of Lovastatin nightly or a placebo for 32 weeks.
- Evaluated changes in lipid profiles, creatinine levels, and adverse events.
Main Results:
- Lovastatin significantly reduced total cholesterol and LDL levels compared to placebo (p < 0.05).
- HDL and triglyceride levels remained unchanged.
- No significant difference in adverse events or a detrimental effect on kidney graft function was observed between groups.
Conclusions:
- Low-dose Lovastatin is a safe and effective cholesterol-lowering treatment for kidney transplant recipients.
- Further research is needed to explore potential long-term benefits on cardiovascular health and graft function.
Abstract:
The high prevalence of hypercholesterolemia (HCh) in kidney transplant recipients probably contributes to the high cardiovascular mortality of these patients. Additionally, HCh is a contributing factor to the progression of renal failure. We conducted a prospective, randomised study with low dose Lovastatin in 42 kidney transplant recipients during 32 weeks, focusing on side effect and kidney function 42 consecutive patients with kidney transplanted in our Institute, with stable renal function (creatinine level < 160 mmol/l) treated with ciclosporine, azathioprine, prednisone were enrolled for the study (regardless of the initial cholesterol level). Every second patient was given Lovastatin 20 mg/night. In the Lovastatin group total cholesterol (TC) and LDL concentration were significantly lower after 6 months of treatment (TC was reduced from 242.5 +/- 12.8 to 220 +/- 15.4 mg/dl, p < 0.05) in Lovastatin group whereas in control group it increased nonsignificantly. Similarly LDL in Lovastatin group decreased from 140.0 +/- 7.0 to 121.3 +/- 10.8 mg/dl, p < 0.02 whereas in control group it increased from 143.6 +/- 5.4 to 169.9 +/- 10.3 mg/dl, p < 0.01. HDL and trigliceride concentrations were unchanged. The Lovastatin treatment did not results in more adverse events than the placebo treatment. Notably, the tendency to increase creatinine level in Lovastatin group was observed from 1.59 +/- 0.17 to 1.74 +/- 0.22 in Lovastatin group versus 1.89 +/- 0.22 to 2.21 +/- 0.35 mg/dl (NS). Low dose Lovastatin treatment seems to be safe and efficient cholesterol-lowering procedure. However we did not observe beneficial effect on kidney graft function.